FREMONT, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that it will host an R&D Update in
New York City on October 15, 2004. The event will be held at the Four Seasons
Hotel, 57 East 57th Street in New York City, beginning at 8:00 a.m. Eastern
time. There will be a webcast available at http://www.pdl.com.
As part of the program, PDL will update the status of and recent data from
its key clinical development programs, including the Nuvion(R) (visilizumab)
antibody product currently in a Phase I / II clinical trial for the potential
treatment of severe steroid-refractory ulcerative colitis; daclizumab in Phase
II for the treatment of patients with moderate-to-severe asthma; and M200, an
anti-alpha5 beta1 antibody currently in a Phase I study in advanced solid
tumors. PDL additionally expects to discuss several of its promising
preclinical development candidates. A mix of senior company representatives
and outside investigators are expected to present the various updates and to
be available for Q&A, as well. More information, including the final agenda
for the event, will be posted at http://www.pdl.com.
Protein Design Labs is a leader in the development of humanized antibodies
to prevent or treat various disease conditions. PDL currently has antibodies
under development for autoimmune and inflammatory conditions, asthma and
cancer. PDL holds fundamental patents for its antibody humanization
technology. Further information on PDL is available at http://www.pdl.com.
NOTE: Protein Design Labs and Nuvion are registered U.S. trademarks and
the PDL logo is considered a trademark of Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
James R. Goff, Senior Director, Corporate
Communications of Protein Design Labs, +1-510-574-1421, or
jgoff@pdl.com
|
